Beiersdorf AG header image

Beiersdorf AG

BEI

Equity

ISIN DE0005200000 / Valor 324660

Xetra (2024-09-18)
EUR 124.20-1.19%

Beiersdorf AG
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Beiersdorf AG is a global company with a business segment called tesa, which has been operating independently since 2001. tesa is a leading manufacturer of self-adhesive product solutions for industrial customers and consumers, known for its superior technology and high-quality products. The company's business strategy is centered around innovation, constantly working to develop effective solutions for its customers.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (07.08.2024):

Revenue Growth

In the first half of 2024, Beiersdorf AG reported a 7.1% increase in organic Group sales compared to the same period in the previous year. This growth was driven by strong performance in both the Consumer Business Segment and the tesa Business Segment. Nominal Group sales rose by 4.8%, reaching €5,175 million, up from €4,936 million in the first half of 2023.

Consumer Business Segment

Beiersdorf AG's Consumer Business Segment saw an 8.0% increase in organic sales in the first half of 2024. This segment's nominal sales grew by 5.4%, amounting to €4,331 million, compared to €4,108 million in the same period of the previous year. The strong performance was attributed to the excellent results of NIVEA and the Derma brands.

Profit After Tax

For the first half of 2024, Beiersdorf AG reported a profit after tax of €590 million, slightly up from €589 million in the same period of 2023. This marginal increase reflects the company's ability to maintain profitability despite various market challenges and cost increases.

EBIT Margin

Beiersdorf AG's EBIT margin excluding special factors stood at 16.2% for the first half of 2024, down from 17.3% in the same period of the previous year. The decrease was primarily due to cost increases related to foreign exchange rate developments, although these were partially offset by price increases and focused spending in marketing, research and development, and digitalization.

Regional Performance

In the first half of 2024, Beiersdorf AG achieved organic sales growth of 5.5% in Europe, 3.0% in the Americas, and 13.5% in the Africa/Asia/Australia region. Nominal sales in these regions were €2,331 million, €1,344 million, and €1,500 million, respectively. The strong performance in the Africa/Asia/Australia region was a significant contributor to the overall growth in Group sales.

Summarized from source with an LLMView Source

Key figures

1.72%1Y
20.2%3Y
13.7%5Y

Performance

14.7%1Y
18.5%3Y
20.2%5Y

Volatility

Market cap

34379 M

Market cap (USD)

Daily traded volume (Shares)

186,210

Daily traded volume (Shares)

1 day high/low

126 / 124.2

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals Inc Rhythm Pharmaceuticals Inc Valor: 25337263
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.88%USD 53.64
Amicus Therapeutics Inc
Amicus Therapeutics Inc Amicus Therapeutics Inc Valor: 2644388
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.59%USD 10.91
Service Corporation International
Service Corporation International Service Corporation International Valor: 969683
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.27%USD 79.54
AMEDISYS Inc
AMEDISYS Inc AMEDISYS Inc Valor: 399513
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.23%USD 97.15
QuidelOrtho Corporation
QuidelOrtho Corporation QuidelOrtho Corporation Valor: 119356965
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.26%USD 46.23
Guardant Health Inc
Guardant Health Inc Guardant Health Inc Valor: 43633454
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.04%USD 25.08
Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc Xenon Pharmaceuticals Inc Valor: 25419823
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%USD 40.09
Hutchmed (China) Limited
Hutchmed (China) Limited Hutchmed (China) Limited Valor: 30165904
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.12%USD 16.32
LivaNova PLC
LivaNova PLC LivaNova PLC Valor: 28726218
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.14%USD 51.07
PTC Therapeutics Inc
PTC Therapeutics Inc PTC Therapeutics Inc Valor: 2515234
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.17%USD 35.48